secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2022-09-29T23:59:59+00:00
Accession:  0001683168-22-006665
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals appoints Robert Bitterman as interim Executive Chairman, effective Sept. 26, 2022
--------------------------------------------------------------------------------

- Robert Bitterman, Board Chairman since 2012, named interim Executive Chairman and principal executive/financial officer.
- Bitterman receives $175,000 annual base salary (incl. $55,000 Board fee) and 40,000 RSUs vesting Oct. 1, 2023.
- Dr. Geert Cauwenbergh ceases as interim principal executive/financial officer and resumes independent Board role.
- Robert Ferrara appointed Lead Independent Director; he chairs the Audit Committee and is a CPA.
- Press release issued Sept. 29, 2022, announcing the leadership changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316822006665/0001683168-22-006665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316822006665/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-006665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer